The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

Sponsor
Neon Hospital
Study ID
NCT02796183
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

Key Dates

First listed
Jun 10, 2016
Start date
Jan 31, 2015
Status verified
Jun 2016
Primary completion
Apr 30, 2016
Completion
May 31, 2016

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Diabetic macular edema
    Bevacizumab (Altuzan) was injected subconjunctival space of the patients.

Primary Outcome Measure

Central Macular Thickness [ Time Frame: one year (between May 2015 and May 2016) ]

Related Studies